Slide 1: Strategic Update: Acquisition of AavantiBio and $75M PIPE
Exhibit 99.2 Strategic Update: Acquisition of AavantiBio and $75M PIPE September 30, 2022 © 2022 Solid Biosciences 1
Slide 2: Forward-Looking Statements and Industry and Market Data
Forward-Looking Statements and Industry and Market Data This presentation and various remarks we make during this presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding: future expectations, plans a
Slide 3: Additional Information about the Transactions
Additional Information about the Transactions No Offer or Solicitation This presentation is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a soli
Slide 4: Introductions
Introductions Ilan Ganot Bo Cumbo Steve DiPalma Co-Founder, President and President and Chief Executive Interim Chief Financial Officer Officer Chief Executive Officer Solid Biosciences AavantiBio Solid Biosciences Jenny Marlowe, Ph.D. Caitlin Lowie Carl Morris, PhD Chief Scientific Officer Chief Sc
Slide 5: Agenda
• Definitive Agreement to Acquire AavantiBio AGENDA • Strategic Path Forward for Solid Biosciences • Q&A © 2022 Solid Biosciences 5
Slide 6: Strategic Update: Diversify Solid's business through merger with AavantiBio
STRATEGIC UPDATE: Diversify Solid’s business through the strategic merger with AavantiBio, supported by PIPE investment expected to extend Solid’s runway into 2025 © 2022 Solid Biosciences 6
Slide 7: Definitive Agreement to Acquire AavantiBio
DEFINITIVE AGREEMENT TO ACQUIRE AAVANTIBIO © 2022 Solid Biosciences 7
Slide 8: Solid Strengthens Pipeline and Organizational Capacity through Acquisition of AavantiBio
Solid Strengthens Pipeline and Organizational Capacity through Strategic Acquisition of AavantiBio Addition of AavantiBio’s Friedreich’s ataxia and cardiac programs presents an opportunity for Solid to become a leading gene therapy company within neuromuscular and cardiac medicine Strategic Rational
Slide 9: Transaction Overview
Transaction Overview Solid has signed a definitive agreement to acquire AavantiBio, supported by an $75M PIPE Ownership PIPE Pro Forma Company • All-stock transaction with AavantiBio • Solid agreed to sell 159,574,463 shares of • Combined company expected to have shareholders to own 15% of pro forma
Slide 10: The Combined Company: Precision Genetic Medicine Company in Neuromuscular and Cardiac Rare Disease
The Combined Company: Precision Genetic Medicine Company In Neuromuscular And Cardiac Rare Disease 2022 2023 2024 Planned merger between IND expected for DMD µDys SGT-003 IND expected for Friedreich's ataxia AVB-202 and IND enabling studies for Solid Bio and AavantiBio Program with Novel Capsid and
Slide 11: Combined Company To Be Led By Experienced Team
Combined Company To Be Led By Experienced Team With Deep Expertise In Precision Genetic Medicine With >100 Combined Years of Relevant Experience Bo Cumbo Stephen DiPalma Carl Morris, PhD Jenny Marlowe, PhD Chief Scientific Officer Chief Scientific Officer President and CEO Interim Chief Friedreich’s
Slide 12: Precision Genetic Platform For Neuromuscular And Cardiac Diseases
Precision Genetic Platform For Neuromuscular And Cardiac Diseases PIPELINE VISION: Goal To Have Multiple INDs and Clinical Programs In The Coming Years The Merger Presents the Opportunity to Prominent Precision Genetic Medicine Company In Become a Leading Gene Therapy Company Cardiac and Neuromuscul
Slide 13: Merger Significantly Expands And Diversifies Pipeline
Merger Significantly Expands And Diversifies Pipeline Diversified Pipeline across Neuromuscular and Cardiac Disease with Indications We Believe are Characterized by High Unmet Need, Clear Mechanistic Rationale and Significant Market Opportunities Research / IND submission Phase I/II* Program Indicat
Slide 14: Duchenne Represents A Large Market Opportunity With Significant Unmet Need
Duchenne Represents A Large Market Opportunity With Significant Unmet Need Proof of concept achieved with SGT-001 and potential for best-in-class with SGT-003 Duchenne Is A Well-suited Gene Therapy Program Via Systemic Microdystrophin Delivery Disease Overview & Epidemiology Planned Approach Key Dis
Slide 15: Clinical Proof Of Concept For SGT-001 Suggests SGT-003 Could Provide Higher Transduction
Clinical Proof Of Concept For SGT-001 (HSV) Suggests SGT-003 (TT) Could Provide Higher Transduction And Lower Viral Loads SGT-001 HSV SGT-001 TT SGT-003 AAV-SLB101 Capsid AAV9 AAV9 (Novel, muscle tropic capsid) Promoter CK8 CK8 CK8 Transgene Protein nNOS Microdystrophin nNOS Microdystrophin nNOS Mic
Slide 16: Data Support Advancement of SGT-003 Toward IND submission in Mid-2023
Data Support Advancement of SGT-003 Toward IND submission in Mid-2023 Capsid has shown increased biodistribution and expression in muscle and cardiac tissue (in vitro and vivo) which may reduce total viral load required Serum CK Day 29 Post-Treatment In Vitro (Mouse & Human) Dystrophic Cell Based As
Slide 17: Solid's Path Forward for SGT-003
Solid’s Path Forward for SGT-003 Manufacturing Regulatory Engagement Clinical scale process development complete; Solid completing preclinical requirements and Solid to initiate GMP manufacturing to enable clinical protocol to support IND submission patient dosing in late-2023, pending IND package a
Slide 18: Friedreich's Ataxia Represents A Large Market Opportunity With Significant Unmet Need
Friedreich’s Ataxia Represents A Large Market Opportunity With Significant Unmet Need And No Approved Therapies FA Is A Well-suited Gene Therapy Program Via Frataxin Replacement Strategy Disease Overview & Epidemiology Planned Approach and Current Status Key Disease Highlights Planned Approach: IND
Slide 19: AVB-202: Potential To Be Best-in-class
AVB-202: Potential To Be Best-in-class Supported by Early Pre-Clinical Proof of Concept for AVB-201 and AVB-202 HSV, Suggests AVB-202 Transient Transfection Could Potentially Be Best-in-Class PoC Pre-Clinical PoC Pre-clinical Proposed Clinical Candidate AVB-201 AVB-202 HSV AVB-202 TT Capsid AAV9 AAV
Slide 20: FA Proof Of Concept Achieved Pre-clinically
FA Proof Of Concept Achieved Pre-clinically Program Supported by Multiple Key Preclinical Models of Cardiac Manifestations of FA AVB-202 Extended Survival And Improved Cardiac Function In Cardiac Frataxin (FXN) KO Mice Survival Ejection Fraction Pre-symptomatic FXN KO model Survival Ejection Fractio
Slide 21: Preclinical Proof Of Principle Via Succinate Dehydrogenase
Preclinical Proof Of Principle Via Succinate Dehydrogenase (SDH): Improved SDH Levels Post Treatment Maintenance Of High SDH Activity Between 9 And 30 Weeks Correlated With Improved Survival In Higher Dose Groups 100 80 60 AVB-202 Preclinical Data (Cardiac Mouse Model) 40 9 30 9 30 9 30 9 30 9 30 9
Slide 22: Dilated Cardiomyopathy (BAG3) Is The First Program From The Cardiac Pipeline
Dilated Cardiomyopathy (BAG3) Is The First Program From The Cardiac Pipeline Attractive Indication with Clear Mechanistic Rationale, High Unmet Need and Significant Market Opportunity BAG3 DCM is Well-suited to Gene Therapy via BAG3 Replacement Disease Overview & Epidemiology Patient Experience and
Slide 23: Capsid Platform Expected To Enhance Tropisms Across Cell Types And Tissues
Capsid Platform Expected To Enhance Tropisms Across Cell Types And Tissues For Early-stage Pipeline Beyond Duchenne, FA And BAG3 Developing Next-generation AAV Capsid Libraries For Targeted Tissue Delivery Developing novel AAV CARDIAC capsids that enhance select Rational Design approach used to engi
Slide 24: Single Manufacturing Approach Across All Programs Utilizing Transient Transfection
Single Manufacturing Approach Across All Programs Utilizing Transient Transfection Combined Company Will Have Fully Integrated CMC Regulatory Teams Supporting PD/AD/QA/QC* Established commercially scalable process with a known regulatory pathway that we believe can be leveraged to move programs quic
Slide 25: In Vivo Comparison Study Supports Use of TT Process and SGT-003 Capsid
In Vivo Comparison Study Supports Use of TT Process and SGT-003 Capsid Process and capsid changes yielded a 2.3x improved expression for SGT-003 TT compared to SGT-001 HSV Microdystrophin Expression (WB) at 1E14 vg/kg in mdx mice ~ 2.3x 400 ~1.7x 350 Process change (HSV to TT) and AAV-SLB101 capsid
Slide 26: Strategic Manufacturing Partnerships And Vector Core To Support Portfolio
Strategic Manufacturing Partnerships And Vector Core To Support Portfolio Process optimization and Manufacturing services cGMP manufacturing and supply for Duchenne Our internal expertise and services for FA capabilities are complemented by a robust network of CDMO partners who provide Internal cust
Slide 27: Anticipated Key Value Inflection Points
Anticipated Key Value Inflection Points Closing of Merger IND Submission for Report functional data following Solid SGT-003 from IGNITE DMD Shareholder Vote Mid-2023 Early-2023 Q4 2022 Initiation of Patient IND Submission for Dosing for SGT-003 AVB-202 Late-2023 2H 2024 Solid expects to have approxi
Slide 28: Q&A
Q&A © 2022 Solid Biosciences 28
Slide 29: Thank You
THANK YOU © 2022 Solid Biosciences 29
Slide 30: Risk Factors
Risk Factors The list below of risk factors has been prepared solely for purposes of the proposed PIPE as part of the proposed Merger between Solid and AavantiBio, and solely for potential investors in the PIPE, and not for any other purpose. The risks presented below are certain of the general risk
Slide 31: Risk Factors: Risks Related to the Proposed Combined Company
Risk Factors Risks Related to the Proposed Combined Company • The combined company will incur net losses for the foreseeable future and may never achieve or maintain profitability. • The combined company will need additional funding, which may not be available on acceptable terms, or at all. Failure